In comparison, the combination of AZD5991 with another cell death target, the Bcl-xL inhibitor (AZ-3202), has poor selectivity with a >25% response rate in 90% (38/41) of tumor types (Supplementary Fig. S5A). This evidence concerns the gene BCL2L1 and neoplasm.